Objective: To examine the real-world effectiveness of secukinumab with regard to clinical
and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in …

Introduction Real-world evidence has demonstrated the effectiveness of secukinumab in the
treatment of psoriasis; however, limited data are available on patient profiles of US …

Background: Little is known about the treatment outcomes of secukinumab in clinical
practice, which differ from those in clinical trials. The effectiveness of biologics may differ in …

A number of randomized controlled trials and real‐world studies have demonstrated the
effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis …

Real‐world evidence (RWE) meta‐analyses provide valuable insights from patients in
routine clinical practice. Secukinumab, the first fully human monoclonal antibody that …

Introduction Secukinumab has demonstrated sustained long-term efficacy with a favourable
safety profile in various manifestations of psoriatic disease. We investigated effectiveness …

Background Randomized controlled trials of secukinumab have shown sustained efficacy
and a favourable safety profile in multiple manifestations of psoriatic disease. Objectives To …

Introduction Information on the long-term treatment satisfaction with secukinumab for
patients with plaque psoriasis in real-world settings is limited. The objective of this study was …

Introduction Psoriasis affecting the head and neck can be difficult to treat, and the presence
of extensive and highly visible lesions may result in substantial psychosocial burdens …

To evaluate drug survival of secukinumab in a daily practice setting, we retrospectively
evaluated all psoriatic patients starting secukinumab during January 2016-February 2017 at …